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Introduction
For the past two decades, the incidence of cutaneous melanoma has steadily increased. In 2010, 68,130 new cases with 8,700 deaths were estimated to have occurred in the US(1). (2) . Identification of effective strategies for the treatment of melanoma remains an urgent need. Recently immunotherapy with anti-CTLA4 antibody has demonstrated improved overall survival when compared to a peptide vaccine for patients with refractory advanced melanoma (3) . Moreover, genetic changes are linked to the intrinsic molecular defects that are identified to be "causal" for tumor development and as a result, therapeutic strategies often target oncogenes (4) (5) (6) 
and GSK2118436] substantially reduced tumor burden in patients with melanoma harboring this mutation (7) . Indeed, BRAF targeted therapy has been approved by the FDA as standard of care for metastatic melanoma patients with proven BRAF mutation (7) (8) (9) (10) (11) . Given the specificity of such small molecule inhibitors, identification of genetically defined patient subgroups is critical to gain better outcomes and avoid drug-induced adverse effects (12, 13) . Moreover, resistance that results after Vemurafenib treatment can result from activation of c-RAF, suggesting combined therapy with an inhibitor that targets multiple kinases, like RAF265, or a MEK inhibitor may be more effective.
RAF265 is an orally bioavailable small molecule with pre-clinical anti-tumor activity that currently is being tested in phase I clinical trials. Much like Sorafenib, in vitro kinase assays show RAF265 inhibits the activities of several intracellular kinases, including BRAF(V600E), BRAF(wild type), c-RAF, VEGFR2, PDGFR, CSF1R, RET and c-KIT, SRC, STE20 and others with IC 50s ranging from <20 to >100nM.
However, in cell based assays RAF265 is most potent for BRAF V600E , BRAF WT and VEGFR2, but less active for PDGFRB and c-KIT (14, 15) [and Stuart et al, submitted]. RAF265 inhibited BRAF-mediated down-stream activation of ERK, which was conceived as the major underlying mechanism for the growth inhibition of human colorectal carcinoma in an orthotopic transplant tumor model (16) . The efficacy of
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Author Manuscript Published OnlineFirst on February 20, 2012 ; DOI: 10.1158/1078-0432.CCR- RAF265 in treating human melanoma is unknown, though the ongoing melanoma Phase I clinical trials are based upon cell line xenograft studies (15) . Because melanoma cells possess multiple mechanisms to invade, metastasize, and resist therapies, the multiple-targeting agents like RAF265 may inhibit the pathways critical for tumor and induce tumor regression. Since limited data are available regarding responsiveness to RAF265, we wished to examine response to this drug in a pre-clinical setting that evaluates the response of melanoma tumors taken directly from the patient, where genetic markers and gene expression profiles which may predict response the drug are determined. The response to RAF265 appeared effective in >70% of BRAF wild type melanomas. In addition, analysis of the global gene expression profile of human melanoma tumor samples revealed differential expression of genes known to be relevant to cell cycle, apoptosis, cell-cell adhesion, epithelial mesenchymal transition, and drug resistance in RAF265 responders compared to non-responders. Using this information, it may be possible to predict which melanoma patients will respond to RAF265.
Materials and Methods

Chemical agent and antibodies
A detailed list of reagents and antibodies is found in the Supplemental Methods section.
Patient characteristics
Thirty-four patients with advanced melanoma underwent surgical resection of regional lymph node or distant metastases between February 2007 and August 2009. A single patient (V30) had a tumor obtained from a locally advanced primary of the heel. All patients gave informed consent to participate in an Institutional Review Board-approved melanoma and cutaneous malignancy tissue repository. Immediately after resection of the tumor, the sample was divided and fresh tissue was placed in medium for subcutaneous implantation into Balb/c nu/Foxn1 athymic nude mice for the evaluation of tumor response to treatment. Other samples were fixed in paraformaldehyde, flash frozen for signaling, or processed in RNA later for gene expression microarray experiments. The remainder of the specimen was sent to pathology for standard histological analyses. The demographic features, pathology, and treatment of patients included in the study are listed in Supplemental and many patients had melanoma metastatic to a lymph node from an unidentified primary site. Most patients received single or multiple immunological, radiation or chemotherapies before enrollment in the study. All patients were followed prospectively and recurrence and death were recorded.
Orthotopic tumor implantation model
Melanoma tissue biopsy was obtained from patients undergoing surgical resection at Vanderbilt University Medical Center. Tissues were implanted into Balb/C nu/Foxn1 athymic nude mice and drug response was evaluated according to the guidelines of the Vanderbilt Institutional Animal Care and Use Committee.
Detailed protocols are located in Supplemental Methods.
Isolation of total RNA from melanoma tissue
At resection, 20-30 mg aliquots of melanoma tissues from patients were immediately placed into cryovials containing 1 ml of RNAlater Solution (Ambion, USA). Sample cryovials were placed at room temperature for 24 h then stored at -70°C until RNA extraction by RNeasy Fibrous Tissue Mini Kit (Qiagen, Maryland, USA) with DNase I digestion, following the manufacturer's protocol.
Genome-wide expression profiling of melanoma
Gene expression profiling was performed in the Vanderbilt Functional Genomics Shared Resource.
Detailed protocols are available in Supplemental Methods.
Western blot analysis:
Western blots were performed as described in Supplemental Methods:
Accession Number
The microarray data were submitted to the GEO repository according to MIAME (Minimum Information About a Microarray Experiment) criteria. The GEO accession number is: GSE30812.
SNaPshot Genotyping Assay
The SNaPshot mutational profiling method is characterized by multiplexed PCR, multiplexed single-base primer extension, followed by capillary electrophoresis. The current assay was designed to detect 43 point mutations in 6 genes (Supplemental Table S2 ). SNaPshot analysis was performed as previously described (17) . Briefly, PCR primers were pooled to amplify the target DNA, and PCR was performed using the et al., submitted). Extension products were applied to capillary electrophoresis in an ABI 3730 analyzer and the data were interpreted using ABI GeneMapper software (version 4.0). Human male genomic DNA (Promega) was used as a wild type control.
Direct dideoxynucleotide-based sequencing
All mutations detected by SNaPshot genotyping assay were confirmed with direct sequencing. Exons with mutations were amplified using a HotStarTaq® Master Mix Kit (Qiagen) and M13-tagged gene-specific were digested using ExoSAP (USB). Sequencing reactions were performed using Applied Biosystems Version 3.1 Big Dye Terminator chemistry and analyzed on an Applied Biosystems 3730XL Sequencer. All sequence chromatograms were read in both forward and reverse directions.
Tissue Microarray analysis
Melanoma tissues were collected and fixed in 4% paraformaldehyde solution for 24 h at room temperature and embedded in paraffin blocks and tissue microarrays were prepared using standard procedures described in detail in Supplemental Materials and Methods. IHC scores were made in reference to positive and negative areas in the cores of tissue controls where +0.5 indicated low staining over ~50% of the cells, +1 indicated a low level of staining over ~80% of the cells, +2 indicated moderate staining over ~80% of the cells, and +3 indicated strong staining over ~80% of the cells. TMA slides were evaluated and scored by Sara Kantrow, M.D., a licensed and board certified dermatopathologist, or by Kelli Boyd, DVM, Ph.D., DACVP, and by at least one other scientist, each of which was blind to treatment protocol.
Statistical Analyses:
Research. Statistical significance was analyzed with Student's t-test, Bernard's exact test, Chi Square, and/or ANOVA.
Results
Patient profile
Among the tissue biopsies or surgical resections from 34 enrolled patients, tumor tissues from 17 patients were successfully grown in nude mice. In this 17-patient cohort, 13 were male and 4 were female. The mean survival time of this cohort from the time the patient was diagnosed was 30 months (range 6-85 months) at the time this study ended. Melanoma lesions were located on trunk and lower limbs. Tumor ulceration was present in 7 patients. Most patients underwent prior single or combined treatments of immunotherapy, radiation therapy and chemotherapy (Table 1A and Supplemental Table S1 ).
Tumor responses to RAF265
Of the 34 patients studied, we had sufficient tumor implant growth for evaluation of response to RAF265 for 17 patients ( 
Melanoma mutational profile and ERK inactivation by RAF265
To further investigate whether RAF265-induced response in human melanoma tissues correlates with melanoma-relevant genomic alterations, SNaPshot mutational profiling designed to survey 43 common somatic point mutations in 6 genes (BRaf, NRas, Gnaq, Gna11 and Ctnnb1) was performed. There were no detectable mutations in Ctnnb1, Gnaq and Gna11, while one sample had a cKit L576P mutation and another had an NRas P61R mutation, ( Figure 1A and Supplemental Table S2 ). Regarding BRAF gene alterations, 8 of 17 samples (47%) were wild type for BRAF, whereas 7 of 17 samples had the V600E mutation (41%) and 2 of 17 theV600K mutation (12%). No tumors had mutations in more than one of these genes. To clarify whether the mutation profile in tumors would be faithfully maintained after being implanted and grown in nude mice, transplant tumor tissues were also subjected to SNaPshot analysis. The mutational profile between each orthotopic transplant and its human tumor counterpart that had not been transplanted to the mouse were identical (data not shown). Genotyping of 7 of the tumors that did not grow as an implant revealed 3 were Braf V600E mutant, 2 had NRas
P61R
, and 2 were Braf WT with no mutation in
NRas or c-Kit. Thus of the 24 tumors genotyped, 50% had BRaf mutation, 12.5% had NRas mutation, and 4% had c-Kit mutation.
As RAF265 was previously shown to inhibit the growth of tumors with Braf V600E mutation and part of the underlying mechanism was related to inhibition of ERK (16), we then asked two questions: (1) whether the responding tumors in the present study had Braf V600E mutation, and (2) whether RAF265-induced inhibition of melanoma growth involved inhibition of pERK. By analyzing data from SNaPshot mutational profiling, we noticed that most responding tumors (5/7, 71%) were Braf WT (Table 1B) and most of the Braf V600E mutant tumors (77%) were RAF265 non-responders (Table 1B) 
RAF265 Inhibits Proliferation or Enhances Apoptosis in Responding Tumors:
Proliferation and apoptosis in tumor implants were evaluated by Ki67 and TUNEL staining. Of the tumor implants responding to RAF265, those from patient V27, V28, V19 and V35 showed a statistically significant reduction (p</=0.05) in Ki67 staining in the tumor implants on mice treated with RAF265 (40mg/Kg QD) (Supplemental Figure S2A ). Tumor implants from patient V33 showed a reduction in Ki67, but the mean reduction did not reach statistical significance (p=0.08). Of these tumors with reduction in Ki67 after RAF265 treatment, one exhibited the BRaf V600E mutation (V27), one had a cKit I576P mutation (V28) and three did not show mutation in any of the genes evaluated in the SNaPshot analysis (V19, V33, V35). V34 carried the NRas Q61R mutation and did not exhibit reduced Ki67 staining with RAF265 treatment.
In addition, two tumors that had a partial response to RAF265 (~30% reduction in tumor volume) exhibited a statistically significant reduction in Ki67 staining in response to RAF265 treatment (V23, V25). Moreover, TMA analysis of total cyclin D1 revealed differences between control and treated tumors for V19, V18, V28, V12, V27, V25 and V05 where there was 54%, 42%, 46%, 39%, 36%, 33% and 22% reduction ( Figure 2B ).
Western blot analysis for phospho-Cyclin on representative responding tumors (V27, V34, V35) revealed strong reduction in phospho-Cyclin D1 in response to RAF265, again suggesting that RAF265 inhibits cell cycle progression in responding tumors (Figure 2A ). In summary, approximately 70% of the RAF265 responding tumors showed a reduction in Ki67 and/or cyclin D1 that correlated with the inhibition of tumor growth in response to this drug (Supplemental Figure S2C) .
Tumors from both vehicle control and RAF265 treated mice had significant levels of apoptosis, based upon TUNEL staining. However, only V19 and V25 showed strong increase in TUNEL staining in the RAF265 treated group. (Supplemental Figure S2B and S2C), andV34 and V23 showed small increases in TUNEL staining compared to vehicle control. Up-regulation of BIM expression is often coincident with induction of apoptosis, since it can bind to and inhibit BCL-2 proteins and also bind and activate BAX (19) .
To obtain additional insight into the ability of RAF265 to induce apoptosis in melanoma tumors, western blot analysis for BIM and for cleaved caspase 3 was performed on representative tumors. We observed that treatment with RAF265 induced BIM EL BIM L and BIM S isoforms (20) in representative RAF 265 responsive tumors (V27, V35), while the non-responding V29 tumor showed minimal change in BIM expression ( Figure 2A ). V34 had an NRas mutation and did not consistently exhibit induction of BIM.in response to RAF265. Since BCL-2, BCL-X L and MCL-1 bind to pro-apoptotic proteins like BAK, and BAX (21) to prevent apoptosis, we compared the levels of pro-apoptotic (BAX) and anti-apoptotic proteins (BCL-2 and MCL1) and BIM in tumors from RAF265 responders and non-responders treated with RAF265 or vehicle control (Figure 2A ). While BIM expression was induced in response to RAF265, we did not observe induction of BAX, BCL-2 or MCL1 in response to RAF265, though significant levels of these proteins were detected. V34 exhibited a reduction in MCL1 in RAF265 treated tumors. Moreover, we did not detect increases in cleaved Caspase 3 in response to the RAF265 in the four responding tumors analyzed by Western blot (Figure 2A ). These data support the data from the TMA analysis where we did not observe increased TUNEL staining in response to RAF265 for RAF265 responders, with the exception of V19, and one partial responder, V25 (Supplemental Figure S2B) . Altogether, these data suggest that sufficient BCL2 and MCL1 may be present in melanoma tumors to override the potential pro-apoptotic effect of enhanced BIM.
Genome-wide expression profiling
Since the RAF265 mediated tumor response occurred mainly among BRAF WT samples (Table 1B) , we directed our focus on human melanomas harboring wild type BRAF. To identify the possible intrinsic molecular characteristics associated with RAF265-induced drug response, we performed a global gene expression profiling assay by Affymetrix Human Gene ST 1.0 Array on human melanoma samples harboring wild type BRAF. We sorted the data and performed unsupervised clustering on the 28,869
interrogated genes, which allowed separation of wild type BRAF human melanoma samples into two major categories, with five responder tumors (V28, V35, V19, V33, V34) in one group and three non-responders (V32, V25 and V24) in the other group (Table 1B, Figure 3 and Table 2A ). Several genes that were expressed at a higher level in RAF265 responding BRAF WT tumors were in the cancer antigen family (CSAG2, MAGEA3, MAGEA2, PRAME, CSAG1) while others are involved in cell cycle (CDK6, SNAI2).
BRAF WT RAF265 responsive tumors also exhibited a lower level of expression of genes involved in transport (SLC16A6, KCNH1, SLCO2A1, ABCD1), metabolism (CLU, ARS1) or signaling (GPR126, GPR39, PLEKHG1). Of interest, based upon Ingenuity Analysis, the primary pathway that linked the differentially expressed genes in the RAF265 responders versus non-responders were involved in cell development and growth regulation ( Figure 4A ). The cell signaling pathways that linked differentially expressed genes in BRAF WT responders compared to BRAF WT non-responders showed hubs around TNF, PI3KR1 and MAGEA3/MAGEA6( Figure 4B ). GSEA analyses were also performed on the gene expression data and many of the genes identified as enriched in GSEA were significantly differentially expressed in the RMA/limma analysis (in Table 2 A-C where ** beside the gene name designates those genes identified as differentially expressed by both analyses). Moreover, the GSEA analysis BRAF WT tumors that did not respond to RAF265 showed enrichment of genes in the MAPK/RAS pathway, cancer, cell death, growth and proliferation (Supplemental Table S4 and Supplemental Figure 6A ).
Using the same procedures described above we analyzed the genes that were differentially expressed in BRAFV 600E/K RAF265-responding versus non-responding tumor implants. There were only two
Research. (Table 1B) . Only two genes were identified to be differentially expressed between BRAF V600E/K RAF265 responders and non-responders: integrinA10 (ITGA10), 8.6-fold elevated in responders, p<0.006); and calcium dependent secretion activator (CADPS), 3.9-fold elevated in responders, p<0.02 (Table 2B) . These genes are involved in cell adhesion and vesicle exocytosis, respectively.
Comparison of the genes differentially expressed in responders versus non-responders, regardless of the BRAF mutation status, Nupr1 was most significantly up-regulated (>9 fold) in responders (adjusted p value=0.045). NUPR1 is a nuclear protein and a transcriptional regulator that is structurally similar to highmobility group family transcriptional regulators involved in stress response and cancer progression.
NUPR1 regulates cell cycle, apoptosis, autophagy, access to chromatin, and is required for regulation of TGFȕ responses (23) . Using less stringent criteria (Hochberg's step-up method) for data analysis we identified 36 more genes with more than 2-fold differential expression (p<0.05) between responder and non-responder tumors (Table 2C) Table 2C . Moreover, RAF265 non-responders showed enrichment in genes involved in the MAPK pathway (MAP3K11) and elevated expression of HRAS and genes involved in cell cycle and cell proliferation (Supplemental Table S4 and Supplemental Figure S6B and S6C). A subset of these genes differentially expressed may prove to be clinically useful to predict responders versus nonresponders.
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Discussion
The RAS-RAF-MEK-ERK signal transduction has been demonstrated as one of the critical pathways for melanoma tumorigenesis, and inactivation of ERK through inhibition of BRAF is dependent on the mutation status of RAS and BRAF (11, 24) (25) (26) . In this study, we observed a 41% (7/17) response rate for orthotopic implants of human melanoma after treatment with RAF265. Earlier Phase II trials demonstrated at most 1/34 patients clinically respond to Sorafenib alone (27) . While the numbers are small, preliminary reports suggests that RAF265 has a higher response rate than Sorafenib in melanoma (28) response to RAF265 treatment of 4/4 responding orthotopic implants of human melanoma tumors based upon Western blot (Figure 2 ). We also saw decreased total CYCLIN D1 in TMA analysis for 4/7 responders and 2/3 partial responders, suggesting cell cycle arrest is a major mechanism of action of RAF265 in melanoma. However, in two RAF265 responders and 2 partial responders there was some increase in TUNEL staining, indicating that induction of apoptosis can also contribute to RAF265 inhibition of melanoma growth.
Our study showed little overlap between the differentially expressed genes in our RAF265 responding versus non-responding melanoma tumors with other signatures reported associated with BRAF-ERK signaling effects (32) (33) (34) . The gene expression profile we identified in association with RAF265 nonresponsive tumors is quite different from that identified by Dry (35) 
FgfR1
, and Col5a1 from the Dry study were also shown to be enriched. (Table 2A, 2C and Supplementary   Table S4 ). Results from these experiments are consistent with RAF265 having significant anti-tumor activity through ERK dependent and independent pathways. Indeed, we observed that tumors that respond to RAF265, regardless of BRAF mutation status, exhibited a 3-fold higher basal expression of PDGFD which regulates cell cycle and VEGF and Notch-1 (36) (Table 2C) , as well as elevated expression of genes involved in glycolysis/gluconeogenesis and energy metabolism, carbon fixation, intracellular transport, and signal transduction, while the non-responding tumors exhibited up regulation of genes involved in nucleic acid synthesis, cell cycle, growth regulation (Supplemental Table S4 ). Though we did not perform gene expression microarray analysis post-treatment, future studies will interrogate changes in gene expression profiles after RAF265 treatment.
Here we report the BRAF WT expression clusters of genes highly expressed in melanoma that regulate proteins involved in cell cycle (CTA family genes including Mage3, Mage2 (37, 38) . CDK6 plays an important role for cell cycle progression and G1/S transition, cell differentiation, apoptosis, tumor development and metastasis (39, 40) . SNAI2 is one of the critical regulators in early phase of EMT (41) , where it is involved in the transcriptional suppression of tumor cell E-cadherin and Puma, as well as the induction of Mt4-mmp (42) (43) (44) . Both MAGEA2 and MAGEA3 function as suppressors of p53 to promote tumor progression (45) (46) (47) , and MAGEA3 can down-regulate p21 and promote Rb phosphorylation (48) , while PRAME may down-regulate genes that modulate apoptosis (49) . Thus, our data indicate that the RAF265 responsive BRAF WT Table 2A . Differentially expressed genes in RAF265 responder melanoma of wild type BRAF. The genes were chosen based on at least 2-fold differential expression, with less than 10 percent False Discovery Rate (FDR), between responder and non-responder tumors. Fold change was noted to have a positive value when the mean expression is greater in the responder compared to non-responder and has a negative value if the mean expression in the responder is lower than in the non-responders. 3B.
Differentially expressed genes in RAF265 responder BRAF-mutant melanoma tumors compared to RAF265 non-responder BRAF mutant melanoma tumors. 3C. Differentially expressed genes in RAF265
responder melanoma compared to RAF265 non-responder, irrespective of BRAF, c-kit, or NRas mutation. These RNA samples were from primary patient tumors so they were labeled P0, for example V28P0 means passage 0 primary melanoma tumor from patient V28. Gene expression of three RNA sample repeats from 
